Policy-driven changes in healthcare spending and the growing significance of generic competition are acting in tandem to force pharmaceutical companies to adopt more cost-effective manufacturing strategies resulting in an upsurge in the level of M&A activity in the industry as drugmakers consolidate to reduce costs, diversify product portfolios and expand geographic footprints. This whitepaper provides an overview of the pharmaceutical manufacturing landscape with a special focus on generics and biopharmaceuticals. PharmaVentures will also share unique insight gained from the divestment of manufacturing operations for some of the world’s leading pharmaceutical companies.